跳至主要内容
临床试验/ITMCTR2000004112
ITMCTR2000004112招募中1 期

The mechanism of Supplemented Liang Xue Xiao Feng Powder(SLXXFP) adjusting blood-heat syndrome psoriasis vulgaris(PV) apoptosis by miR-203-SOCS3-JAK2/STAT3 double-inhibitory pathway

Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 70(—)
性别
All

入选标准

  • 1. Meet the diagnosis of PV;
  • 2. A diagnosis of blood-heat syndrome;
  • 3. Aged 18 to 70 years;
  • 4. Voluntarily participate in this study; Ability to sign informed consent; Agree to accept the treatment.

排除标准

  • 1. With other skin diseases;
  • 2. With other Severe systemic chronic wasting disease;
  • 3. With mental disease;
  • 4. Received systemic glucocorticoids, retinoids or methotrexate medication within a month, or who received topical glucocorticoids within 2 weeks;
  • 5. Scar diathesis.

研究者

发起方
Hospital of Chengdu University of Traditional Chinese Medicine

相似试验

The mechanism of Supplemented Liang Xue Xiao Feng... | 临床试验